Inhibition of DNA and histone methylation by 5-Aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells

Richard L. Momparler, Sylvie Côté, Louise F. Momparler, Youssef Idaghdhour

Research output: Contribution to journalArticle

Abstract

Epigenetic alterations play an important role in the development of acute myeloid leukemia (AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the key epigenetic changes in AML is gene silencing by DNA methylation. The importance of this alteration is illustrated by the induction of remissions in AML by 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second agent should be sought to increase the efficacy of this epigenetic therapy. An interesting candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker for gene silencing. This second epigenetic silencing mechanism also plays an important role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR in combination with DZNep exhibits a synergistic antineoplastic action against human HL-60 AML cells and the synergistic activation of several tumor suppressor genes. In this report, we showed that this combination also induced a synergistic activation of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 cells was investigated in greater depth using RNA sequencing analysis. We observed that this combination of epigenetic agents exhibited a synergistic activation of hundreds of genes. The synergistic activation of so many genes that suppress malignancy by 5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone methylation plays a major role in leukemogenesis. Targeting DNA and histone methylation is a promising approach that merits clinical investigation for the treatment of AML.

Original languageEnglish (US)
Article number19
JournalFrontiers in Oncology
Volume7
Issue numberFEB
DOIs
StatePublished - Feb 15 2017

Fingerprint

decitabine
Myeloid Cells
DNA Methylation
Acute Myeloid Leukemia
Antineoplastic Agents
Histones
Epigenomics
Gene Expression
Gene Silencing
HL-60 Cells
Histone-Lysine N-Methyltransferase
RNA Sequence Analysis
Remission Induction
Myeloid Leukemia
3-deazaneplanocin
Tumor Suppressor Genes
Transcriptional Activation

Keywords

  • 3-deazaneplanocin A
  • 5-aza-2-deoxycytidine
  • Chemotherapy
  • Epigenetics
  • Gene expression
  • Myeloid leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of DNA and histone methylation by 5-Aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells. / Momparler, Richard L.; Côté, Sylvie; Momparler, Louise F.; Idaghdhour, Youssef.

In: Frontiers in Oncology, Vol. 7, No. FEB, 19, 15.02.2017.

Research output: Contribution to journalArticle

@article{9b2a76c0613048909cd875ce23865ebb,
title = "Inhibition of DNA and histone methylation by 5-Aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells",
abstract = "Epigenetic alterations play an important role in the development of acute myeloid leukemia (AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the key epigenetic changes in AML is gene silencing by DNA methylation. The importance of this alteration is illustrated by the induction of remissions in AML by 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second agent should be sought to increase the efficacy of this epigenetic therapy. An interesting candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker for gene silencing. This second epigenetic silencing mechanism also plays an important role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR in combination with DZNep exhibits a synergistic antineoplastic action against human HL-60 AML cells and the synergistic activation of several tumor suppressor genes. In this report, we showed that this combination also induced a synergistic activation of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 cells was investigated in greater depth using RNA sequencing analysis. We observed that this combination of epigenetic agents exhibited a synergistic activation of hundreds of genes. The synergistic activation of so many genes that suppress malignancy by 5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone methylation plays a major role in leukemogenesis. Targeting DNA and histone methylation is a promising approach that merits clinical investigation for the treatment of AML.",
keywords = "3-deazaneplanocin A, 5-aza-2-deoxycytidine, Chemotherapy, Epigenetics, Gene expression, Myeloid leukemia",
author = "Momparler, {Richard L.} and Sylvie C{\^o}t{\'e} and Momparler, {Louise F.} and Youssef Idaghdhour",
year = "2017",
month = "2",
day = "15",
doi = "10.3389/fonc.2017.00019",
language = "English (US)",
volume = "7",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Inhibition of DNA and histone methylation by 5-Aza-2'-deoxycytidine (decitabine) and 3-deazaneplanocin-A on antineoplastic action and gene expression in myeloid leukemic cells

AU - Momparler, Richard L.

AU - Côté, Sylvie

AU - Momparler, Louise F.

AU - Idaghdhour, Youssef

PY - 2017/2/15

Y1 - 2017/2/15

N2 - Epigenetic alterations play an important role in the development of acute myeloid leukemia (AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the key epigenetic changes in AML is gene silencing by DNA methylation. The importance of this alteration is illustrated by the induction of remissions in AML by 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second agent should be sought to increase the efficacy of this epigenetic therapy. An interesting candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker for gene silencing. This second epigenetic silencing mechanism also plays an important role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR in combination with DZNep exhibits a synergistic antineoplastic action against human HL-60 AML cells and the synergistic activation of several tumor suppressor genes. In this report, we showed that this combination also induced a synergistic activation of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 cells was investigated in greater depth using RNA sequencing analysis. We observed that this combination of epigenetic agents exhibited a synergistic activation of hundreds of genes. The synergistic activation of so many genes that suppress malignancy by 5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone methylation plays a major role in leukemogenesis. Targeting DNA and histone methylation is a promising approach that merits clinical investigation for the treatment of AML.

AB - Epigenetic alterations play an important role in the development of acute myeloid leukemia (AML) by silencing of genes that suppress leukemogenesis and differentiation. One of the key epigenetic changes in AML is gene silencing by DNA methylation. The importance of this alteration is illustrated by the induction of remissions in AML by 5-aza-2'-deoxycytidine (5-AZA-CdR, decitabine), a potent inhibitor of DNA methylation. However, most patients induced into remission by 5-AZA-CdR will relapse, suggesting that a second agent should be sought to increase the efficacy of this epigenetic therapy. An interesting candidate for this purpose is 3-deazaneplanocin A (DZNep). This analog inhibits EZH2, a histone methyltransferase that trimethylates lysine 27 histone H3 (H3K27me3), a marker for gene silencing. This second epigenetic silencing mechanism also plays an important role in leukemogenesis as shown in preclinical studies where DZNep exhibits potent inhibition of colony formation by AML cells. We reported previously that 5-AZA-CdR in combination with DZNep exhibits a synergistic antineoplastic action against human HL-60 AML cells and the synergistic activation of several tumor suppressor genes. In this report, we showed that this combination also induced a synergistic activation of apoptosis in HL-60 cells. The synergistic antineoplastic action of 5-AZA-CdR plus DZNep was also observed on a second human myeloid leukemia cell line, AML-3. In addition, 5-AZA-CdR in combination with the specific inhibitors of EZH2, GSK-126, or GSK-343, also exhibited a synergistic antineoplastic action on both HL-60 and AML-3. The combined action of 5-AZA-CdR and DZNep on global gene expression in HL-60 cells was investigated in greater depth using RNA sequencing analysis. We observed that this combination of epigenetic agents exhibited a synergistic activation of hundreds of genes. The synergistic activation of so many genes that suppress malignancy by 5-AZA-CdR plus DZNep suggests that epigenetic gene silencing by DNA and histone methylation plays a major role in leukemogenesis. Targeting DNA and histone methylation is a promising approach that merits clinical investigation for the treatment of AML.

KW - 3-deazaneplanocin A

KW - 5-aza-2-deoxycytidine

KW - Chemotherapy

KW - Epigenetics

KW - Gene expression

KW - Myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=85014781242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014781242&partnerID=8YFLogxK

U2 - 10.3389/fonc.2017.00019

DO - 10.3389/fonc.2017.00019

M3 - Article

AN - SCOPUS:85014781242

VL - 7

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - FEB

M1 - 19

ER -